See the DrugPatentWatch profile for Roflumilast
Roflumilast is marketed under the trade name Daliresp [1][2][3].
What is Daliresp (roflumilast) used for?
Daliresp is a medication used to reduce the risk of exacerbations (worsening symptoms) in patients with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis [1][2]. It is not intended for the immediate relief of bronchospasm or as a rescue inhaler [1].
How does roflumilast work?
Roflumilast is a selective phosphodiesterase 4 (PDE4) inhibitor [1]. By inhibiting PDE4, it increases intracellular cyclic AMP (cAMP) levels in lung cells. This mechanism helps to reduce inflammation and mucus production, which are key components of COPD exacerbations [1].
What are the potential side effects of Daliresp?
Common side effects reported with Daliresp include diarrhea, nausea, headache, weight loss, and abdominal pain [1][2]. It is important for patients to discuss any side effects with their healthcare provider.
Are there other medications for COPD exacerbations?
Yes, other classes of medications are used to manage COPD exacerbations, including inhaled bronchodilators (long-acting beta-agonists and long-acting muscarinic antagonists) and inhaled corticosteroids [1]. Roflumilast is typically used in addition to these treatments for patients with severe COPD and a history of exacerbations [1].
When does the patent for Daliresp expire?
Information regarding the specific patent expiry dates for Daliresp is available through resources like DrugPatentWatch.com [4]. Patent protection generally grants a period of market exclusivity to the innovator drug.
Can generic versions of roflumilast be made available?
Once patents expire, or if they are successfully challenged, generic versions of roflumilast may become available. The development and approval of generic drugs require demonstrating bioequivalence to the brand-name product.
What clinical data supports the use of roflumilast?
Clinical trials have evaluated the efficacy and safety of roflumilast in reducing COPD exacerbations. These studies have shown a statistically significant reduction in the rate of moderate to severe exacerbations in specific patient populations with severe COPD [1].
What are the risks associated with roflumilast?
While roflumilast offers benefits for managing COPD exacerbations, potential risks include gastrointestinal issues and weight loss [1][2]. Patients with a history of depression or suicidal ideation should be monitored, as these have been reported in some cases [1][2]. It is crucial for healthcare providers to weigh the benefits against the risks for each individual patient.
Who manufactures Daliresp?
Daliresp is manufactured by AstraZeneca [3].
Sources:
[1] https://www.drugs.com/mtm/daliresp-oral.html
[2] https://www.webmd.com/drugs/2/154844/roflumilast-oral
[3] https://www.rxlist.com/daliresp-drug.htm
[4] https://drugpatentwatch.com